 Ruofei Du
Concepts (249)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnant Women | 2 | 2023 | 70 | 0.840 |
Why?
| | Hypoxia-Ischemia, Brain | 5 | 2021 | 60 | 0.830 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 134 | 0.650 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 30 | 0.630 |
Why?
| | Metagenomics | 3 | 2015 | 40 | 0.630 |
Why?
| | Papillomavirus Infections | 4 | 2023 | 172 | 0.630 |
Why?
| | Pregnancy Complications | 1 | 2023 | 400 | 0.620 |
Why?
| | Neurons | 5 | 2021 | 418 | 0.600 |
Why?
| | Lower Extremity | 1 | 2019 | 99 | 0.600 |
Why?
| | Venous Thrombosis | 1 | 2019 | 90 | 0.590 |
Why?
| | Ultrasonography | 1 | 2019 | 424 | 0.560 |
Why?
| | Uterine Cervical Dysplasia | 3 | 2023 | 51 | 0.540 |
Why?
| | Neoplasms | 3 | 2022 | 1305 | 0.490 |
Why?
| | Uterine Cervical Neoplasms | 3 | 2023 | 299 | 0.480 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2013 | 48 | 0.410 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2021 | 179 | 0.410 |
Why?
| | DNA Replication | 2 | 2024 | 160 | 0.400 |
Why?
| | Sequence Analysis, DNA | 1 | 2013 | 230 | 0.380 |
Why?
| | Arsenic | 2 | 2021 | 22 | 0.330 |
Why?
| | Animals, Newborn | 5 | 2021 | 366 | 0.320 |
Why?
| | Neurogenesis | 2 | 2021 | 27 | 0.320 |
Why?
| | Early Detection of Cancer | 5 | 2023 | 183 | 0.310 |
Why?
| | Humans | 32 | 2025 | 52336 | 0.300 |
Why?
| | DNA Ligases | 2 | 2024 | 4 | 0.280 |
Why?
| | Genetic Counseling | 2 | 2017 | 44 | 0.260 |
Why?
| | Female | 18 | 2024 | 28105 | 0.250 |
Why?
| | Capacity Building | 1 | 2025 | 26 | 0.230 |
Why?
| | Social Justice | 1 | 2025 | 33 | 0.230 |
Why?
| | Cervix Uteri | 2 | 2023 | 49 | 0.230 |
Why?
| | Phthalazines | 1 | 2024 | 20 | 0.230 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2024 | 30 | 0.230 |
Why?
| | China | 2 | 2024 | 134 | 0.230 |
Why?
| | Pregnancy | 5 | 2023 | 2675 | 0.230 |
Why?
| | Brain | 3 | 2021 | 1323 | 0.220 |
Why?
| | Young Adult | 7 | 2024 | 4319 | 0.220 |
Why?
| | Piperazines | 1 | 2024 | 117 | 0.210 |
Why?
| | Mass Screening | 3 | 2023 | 357 | 0.210 |
Why?
| | Lymphoma | 1 | 2024 | 71 | 0.210 |
Why?
| | MicroRNAs | 2 | 2021 | 387 | 0.210 |
Why?
| | Morbidity | 1 | 2023 | 141 | 0.200 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2023 | 69 | 0.200 |
Why?
| | United States | 5 | 2025 | 5182 | 0.200 |
Why?
| | Cell Survival | 2 | 2021 | 602 | 0.200 |
Why?
| | Autophagy | 2 | 2021 | 197 | 0.200 |
Why?
| | Adult | 11 | 2024 | 14139 | 0.200 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1110 | 0.200 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2021 | 196 | 0.190 |
Why?
| | Caregivers | 1 | 2024 | 238 | 0.190 |
Why?
| | New Mexico | 4 | 2023 | 12 | 0.180 |
Why?
| | Comorbidity | 1 | 2023 | 624 | 0.180 |
Why?
| | Radiation Protection | 1 | 2021 | 47 | 0.180 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2021 | 1 | 0.180 |
Why?
| | Syntaxin 1 | 1 | 2021 | 3 | 0.180 |
Why?
| | Socioeconomic Factors | 2 | 2021 | 606 | 0.180 |
Why?
| | Breast Neoplasms | 3 | 2020 | 1206 | 0.180 |
Why?
| | Apigenin | 1 | 2021 | 7 | 0.180 |
Why?
| | Hospital Records | 1 | 2021 | 3 | 0.180 |
Why?
| | Glucuronates | 1 | 2021 | 22 | 0.180 |
Why?
| | Mucositis | 1 | 2021 | 8 | 0.180 |
Why?
| | Apoptosis | 3 | 2021 | 1127 | 0.180 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2021 | 28 | 0.180 |
Why?
| | Drug Eruptions | 1 | 2021 | 14 | 0.180 |
Why?
| | Medicaid | 1 | 2023 | 264 | 0.180 |
Why?
| | Histones | 1 | 2023 | 316 | 0.170 |
Why?
| | Precancerous Conditions | 1 | 2021 | 85 | 0.170 |
Why?
| | B-Lymphocytes | 1 | 2021 | 185 | 0.170 |
Why?
| | Animals | 11 | 2024 | 13523 | 0.170 |
Why?
| | Medically Underserved Area | 1 | 2020 | 46 | 0.170 |
Why?
| | Prevalence | 1 | 2023 | 1007 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 643 | 0.170 |
Why?
| | Fatigue | 1 | 2021 | 125 | 0.170 |
Why?
| | Genetic Therapy | 1 | 2021 | 120 | 0.170 |
Why?
| | Neoplasm Metastasis | 1 | 2021 | 240 | 0.170 |
Why?
| | Incidence | 2 | 2021 | 1059 | 0.170 |
Why?
| | Receptors, Tachykinin | 1 | 2019 | 3 | 0.160 |
Why?
| | Mammography | 1 | 2020 | 97 | 0.160 |
Why?
| | Rats, Sprague-Dawley | 5 | 2021 | 1552 | 0.160 |
Why?
| | Cerebral Cortex | 1 | 2021 | 198 | 0.160 |
Why?
| | Gastrointestinal Diseases | 1 | 2021 | 125 | 0.160 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 443 | 0.160 |
Why?
| | Telephone | 2 | 2017 | 71 | 0.160 |
Why?
| | Middle Aged | 8 | 2024 | 13014 | 0.160 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 484 | 0.160 |
Why?
| | Nutrition Surveys | 1 | 2020 | 117 | 0.160 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2020 | 58 | 0.160 |
Why?
| | Nutritional Status | 1 | 2020 | 137 | 0.160 |
Why?
| | Prostatic Neoplasms | 1 | 2023 | 400 | 0.150 |
Why?
| | Thrombosis | 1 | 2021 | 253 | 0.150 |
Why?
| | Receptor, Nerve Growth Factor | 1 | 2018 | 2 | 0.150 |
Why?
| | alpha-Synuclein | 1 | 2018 | 9 | 0.150 |
Why?
| | Parkinsonian Disorders | 1 | 2018 | 12 | 0.150 |
Why?
| | Uranium | 1 | 2018 | 1 | 0.150 |
Why?
| | Ubiquitination | 1 | 2018 | 57 | 0.150 |
Why?
| | Developmental Disabilities | 1 | 2019 | 121 | 0.150 |
Why?
| | Papillomaviridae | 3 | 2023 | 105 | 0.140 |
Why?
| | Pluripotent Stem Cells | 1 | 2017 | 8 | 0.140 |
Why?
| | Rats | 5 | 2021 | 3202 | 0.140 |
Why?
| | GABAergic Neurons | 1 | 2017 | 10 | 0.140 |
Why?
| | Thyroid Hormones | 1 | 2017 | 22 | 0.140 |
Why?
| | Zinc | 1 | 2018 | 56 | 0.140 |
Why?
| | Organoplatinum Compounds | 1 | 2017 | 14 | 0.140 |
Why?
| | Alzheimer Disease | 1 | 2021 | 331 | 0.140 |
Why?
| | Deoxycytidine | 1 | 2017 | 29 | 0.140 |
Why?
| | Bile Duct Neoplasms | 1 | 2017 | 28 | 0.140 |
Why?
| | Pandemics | 1 | 2022 | 585 | 0.140 |
Why?
| | Retrospective Studies | 4 | 2023 | 6578 | 0.140 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2017 | 146 | 0.130 |
Why?
| | Environmental Pollutants | 1 | 2018 | 106 | 0.130 |
Why?
| | Genetic Testing | 1 | 2017 | 130 | 0.130 |
Why?
| | Genes, BRCA2 | 1 | 2016 | 13 | 0.130 |
Why?
| | Genes, BRCA1 | 1 | 2016 | 19 | 0.130 |
Why?
| | Ovarian Neoplasms | 2 | 2017 | 459 | 0.130 |
Why?
| | Papillomavirus Vaccines | 1 | 2017 | 69 | 0.130 |
Why?
| | Computational Biology | 2 | 2021 | 211 | 0.120 |
Why?
| | Diet | 1 | 2020 | 588 | 0.120 |
Why?
| | Hypertension | 1 | 2021 | 565 | 0.120 |
Why?
| | Prognosis | 1 | 2021 | 2094 | 0.120 |
Why?
| | Quality of Life | 1 | 2021 | 868 | 0.120 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2017 | 200 | 0.120 |
Why?
| | Genes, Bacterial | 1 | 2014 | 52 | 0.110 |
Why?
| | Aged | 4 | 2022 | 10109 | 0.110 |
Why?
| | Male | 7 | 2024 | 26696 | 0.110 |
Why?
| | Data Interpretation, Statistical | 1 | 2014 | 164 | 0.110 |
Why?
| | Mutation | 2 | 2017 | 1351 | 0.110 |
Why?
| | Liver Neoplasms | 1 | 2017 | 332 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2018 | 810 | 0.100 |
Why?
| | Aged, 80 and over | 1 | 2021 | 3391 | 0.100 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2014 | 85 | 0.100 |
Why?
| | Treatment Outcome | 2 | 2021 | 5407 | 0.100 |
Why?
| | Chromatin | 2 | 2024 | 141 | 0.100 |
Why?
| | Databases, Genetic | 1 | 2013 | 83 | 0.100 |
Why?
| | Stroke | 1 | 2017 | 509 | 0.100 |
Why?
| | Genome, Human | 1 | 2013 | 121 | 0.100 |
Why?
| | Evolution, Molecular | 1 | 2013 | 95 | 0.100 |
Why?
| | Seroepidemiologic Studies | 2 | 2022 | 44 | 0.100 |
Why?
| | Mice | 4 | 2024 | 5965 | 0.100 |
Why?
| | Adolescent | 5 | 2022 | 6692 | 0.090 |
Why?
| | Cohort Studies | 3 | 2022 | 1532 | 0.090 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 192 | 0.090 |
Why?
| | PC12 Cells | 2 | 2021 | 25 | 0.090 |
Why?
| | Disease Models, Animal | 3 | 2021 | 1484 | 0.090 |
Why?
| | DNA | 2 | 2024 | 550 | 0.090 |
Why?
| | Child Development | 2 | 2021 | 200 | 0.070 |
Why?
| | Infant | 3 | 2022 | 3684 | 0.070 |
Why?
| | Arkansas | 2 | 2025 | 2028 | 0.070 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 1676 | 0.070 |
Why?
| | Registries | 2 | 2021 | 580 | 0.060 |
Why?
| | Obesity | 1 | 2014 | 1162 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2021 | 1589 | 0.060 |
Why?
| | Family Relations | 1 | 2024 | 23 | 0.060 |
Why?
| | Child, Preschool | 2 | 2022 | 4030 | 0.050 |
Why?
| | Human papillomavirus 16 | 1 | 2023 | 44 | 0.050 |
Why?
| | DNA Polymerase III | 1 | 2023 | 5 | 0.050 |
Why?
| | Vaginal Smears | 1 | 2023 | 28 | 0.050 |
Why?
| | Family | 1 | 2024 | 174 | 0.050 |
Why?
| | Facial Expression | 1 | 2022 | 14 | 0.050 |
Why?
| | Models, Statistical | 2 | 2015 | 230 | 0.050 |
Why?
| | Cross-Cultural Comparison | 1 | 2022 | 26 | 0.050 |
Why?
| | Eye Movements | 1 | 2022 | 21 | 0.050 |
Why?
| | Adaptation, Psychological | 1 | 2024 | 229 | 0.050 |
Why?
| | Prostate | 1 | 2023 | 117 | 0.050 |
Why?
| | Employment | 1 | 2022 | 93 | 0.050 |
Why?
| | Genotype | 1 | 2023 | 569 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2023 | 147 | 0.050 |
Why?
| | Lead | 1 | 2021 | 33 | 0.050 |
Why?
| | Antibodies, Viral | 1 | 2022 | 110 | 0.050 |
Why?
| | Survivors | 1 | 2022 | 118 | 0.050 |
Why?
| | Cell Line | 1 | 2024 | 1045 | 0.050 |
Why?
| | Platelet Glycoprotein GPIb-IX Complex | 1 | 2021 | 51 | 0.050 |
Why?
| | Minority Groups | 1 | 2022 | 135 | 0.050 |
Why?
| | Maze Learning | 1 | 2021 | 35 | 0.050 |
Why?
| | Neurites | 1 | 2021 | 14 | 0.050 |
Why?
| | Nerve Regeneration | 1 | 2021 | 20 | 0.050 |
Why?
| | Amyloid beta-Peptides | 1 | 2021 | 66 | 0.050 |
Why?
| | Receptors, Growth Factor | 1 | 2021 | 7 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2021 | 122 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2021 | 73 | 0.050 |
Why?
| | Rats, Transgenic | 1 | 2021 | 21 | 0.050 |
Why?
| | Axons | 1 | 2021 | 48 | 0.040 |
Why?
| | Emotions | 1 | 2022 | 174 | 0.040 |
Why?
| | Maternal Exposure | 1 | 2021 | 101 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 99 | 0.040 |
Why?
| | Mexico | 1 | 2020 | 37 | 0.040 |
Why?
| | Electronic Health Records | 1 | 2022 | 269 | 0.040 |
Why?
| | Receptors, Neurokinin-3 | 1 | 2019 | 1 | 0.040 |
Why?
| | Breast | 1 | 2020 | 85 | 0.040 |
Why?
| | Protein Binding | 1 | 2021 | 680 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2020 | 274 | 0.040 |
Why?
| | Alternative Splicing | 1 | 2019 | 62 | 0.040 |
Why?
| | Problem Solving | 1 | 2019 | 42 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2021 | 193 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2019 | 120 | 0.040 |
Why?
| | Glucose | 1 | 2021 | 357 | 0.040 |
Why?
| | Mothers | 1 | 2021 | 268 | 0.040 |
Why?
| | Psychomotor Performance | 1 | 2019 | 126 | 0.040 |
Why?
| | Rotenone | 1 | 2018 | 15 | 0.040 |
Why?
| | Dopaminergic Neurons | 1 | 2018 | 19 | 0.040 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 32 | 0.040 |
Why?
| | Psychometrics | 1 | 2019 | 230 | 0.040 |
Why?
| | Qualitative Research | 1 | 2020 | 362 | 0.040 |
Why?
| | COUP Transcription Factor II | 1 | 2017 | 1 | 0.040 |
Why?
| | Indians, North American | 1 | 2018 | 36 | 0.040 |
Why?
| | BRCA2 Protein | 1 | 2017 | 19 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 943 | 0.040 |
Why?
| | Thyrotropin | 1 | 2017 | 49 | 0.040 |
Why?
| | Random Allocation | 1 | 2018 | 287 | 0.040 |
Why?
| | BRCA1 Protein | 1 | 2017 | 34 | 0.030 |
Why?
| | Thyroxine | 1 | 2017 | 48 | 0.030 |
Why?
| | Communication | 1 | 2019 | 257 | 0.030 |
Why?
| | Inflammation | 1 | 2021 | 642 | 0.030 |
Why?
| | Mitochondria | 1 | 2021 | 428 | 0.030 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2018 | 140 | 0.030 |
Why?
| | Health Expenditures | 1 | 2017 | 73 | 0.030 |
Why?
| | Age Distribution | 1 | 2017 | 174 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 879 | 0.030 |
Why?
| | Glutamic Acid | 1 | 2017 | 105 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 506 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2018 | 251 | 0.030 |
Why?
| | Insurance, Health | 1 | 2017 | 131 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2018 | 216 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 1903 | 0.030 |
Why?
| | Brain Ischemia | 1 | 2017 | 161 | 0.030 |
Why?
| | Parents | 1 | 2019 | 331 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 558 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2017 | 140 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 1214 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 671 | 0.030 |
Why?
| | Mucus | 1 | 2014 | 4 | 0.030 |
Why?
| | Transcriptome | 1 | 2017 | 367 | 0.030 |
Why?
| | Saliva | 1 | 2014 | 56 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 1436 | 0.030 |
Why?
| | ROC Curve | 1 | 2014 | 251 | 0.030 |
Why?
| | Signal Transduction | 1 | 2021 | 1716 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2018 | 1006 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2014 | 108 | 0.030 |
Why?
| | RNA Precursors | 1 | 2013 | 9 | 0.030 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2014 | 187 | 0.030 |
Why?
| | Nucleic Acid Conformation | 1 | 2013 | 85 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2013 | 155 | 0.020 |
Why?
| | Models, Genetic | 1 | 2013 | 172 | 0.020 |
Why?
| | Sample Size | 1 | 2012 | 44 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 2428 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1031 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2014 | 1201 | 0.020 |
Why?
| | Computer Simulation | 1 | 2012 | 290 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 2268 | 0.020 |
Why?
| | Research Design | 1 | 2012 | 354 | 0.020 |
Why?
| | Child | 1 | 2022 | 7157 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2015 | 561 | 0.020 |
Why?
|
|
Du's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|